The biology of hormone refractory prostate cancer. Why does it develop?
Isaacs JT • 1999 • Urol Clin North Am. 1999;26(2):263-73.
© 2024 Corcept Therapeutics, Incorporated
About jeremiah@devisedesigns.com
This author has not written his bio yet.
But we are proud to say that jeremiah@devisedesigns.com contributed 136 entries already.
Entries by jeremiah@devisedesigns.com
Minireview: nuclear receptors and breast cancer.
Conzen SD • 2008 • Mol Endocrinol.2008;22(10):2215-28.
“Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
Nanda R. • 2011 • Semin Oncol. 2011;38(2):254-62.
Steroid receptors aplenty in prostate cancer.
Sharifi N. • 2014 • N Engl J Med. 2014;370(10):970-1.
Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.
Block et al. • 2017 • Cancer Manag Res. 2017;9:65-72.
Mifepristone treatment of olanzapine-induced weight gain in healthy men.
Gross et al. • 2009 • Adv Ther. 2009;26(10):959-69.
Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
Gross et al. • 2010 • Obesity (Silver Spring). 2010;18(12):2295-300.
The efficacy of mifepristone in the reduction and prevention of olanzapine-induced weight gain in rats.
Beebe et al. • 2006 • Behav Brain Res. 2006;171(2):225-9.
Selective glucocorticoid receptor (type II) antagonists prevent weight gain caused by olanzapine in rats.
Belanoff et al. • 2011 • Eur J Pharmacol. 2011;655(1-3):117-20.
Selective glucocorticoid receptor (GR-II) antagonist reduces body weight gain in mice.
Asagami et al. • 2011 • J Nutr Metab. 2011;2011:235389.